Core Viewpoint - Jiangsu Hualv Biological Technology Group Co., Ltd. has announced the results of the second vesting period for its 2023 restricted stock incentive plan, confirming that the vesting conditions have been met and detailing the distribution of shares [1][13][19]. Summary by Sections 1. Overview of the 2023 Restricted Stock Incentive Plan - The plan includes a total of 400,000 shares, with 82.45% allocated to the first vesting period and 17.55% reserved for future grants [1][12]. - The plan is valid for a maximum of 48 months from the date of grant [2]. 2. Vesting Schedule - The vesting schedule is divided into three periods: - First vesting period: 30% after 12 months - Second vesting period: 40% after 24 months - Third vesting period: 30% after 36 months [2][3][14]. 3. Performance Assessment Criteria - The performance assessment for the first vesting period requires a minimum revenue growth of 20% or net profit growth of 20% based on 2022 figures [4][5]. - For the second vesting period, the targets are set at 30% growth, and for the third period, 40% growth [4][5][15]. 4. Share Distribution and Conditions - A total of 1,247,200 shares were vested to 35 eligible participants, with 40% of the granted shares being vested [13][16]. - Six participants left the company, resulting in the cancellation of 180,000 shares that were not vested [16][19]. 5. Legal and Regulatory Compliance - The company has complied with all necessary legal and regulatory requirements for the vesting and cancellation of shares, as confirmed by legal opinions and audit reports [19][20]. 6. Financial Impact - Following the vesting, the total share capital will increase from 120,202,400 shares to 121,449,600 shares, which may dilute earnings per share [19]. - The funds raised from the share issuance will be used to supplement the company's working capital [18]. 7. Future Considerations - The company will continue to monitor performance against the set targets for future vesting periods and will adjust the incentive plan as necessary based on market conditions [6][17].
华绿生物: 关于2023年限制性股票激励计划首次授予部分第二个归属期归属结果暨股份上市的公告